MedTrace Logo

CyberKnife Stereotactic Radiosurgery for Low and Intermediate Risk Prostate Cancer

NCT02070952 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 167

Last updated 2014-02-25

No results posted yet for this study

Summary

The purpose of this study is to determine the side effects and how effective CyberKnife stereotactic ablative body radiation (SABR) is in patients with prostate cancer. The CyberKnife system is a new type of radiation machine that uses a special system to precisely focus large doses of x-rays on the tumor. The device is designed to concentrate large doses of radiation onto the tumor so that injury from radiation to the nearby normal tissue will be minimal. The purpose of this evaluation is to see if this treatment will help patients with low to intermediate risk prostate cancer and to evaluate the effect of this treatment on the patients' quality of life over time.

Conditions

Interventions

RADIATION

CyberKnife Stereotactic Ablative Body Radiation Therapy

The prescribed planned tumor volume (PTV) dose of 36.25 Gy shall be given in 5 fractions using CyberKnife Hypofractionated Stereotactic Ablative Body Radiation Therapy. PTV will be defined per parameters outlined in the protocol and will at minimum include the entire prostate gland.

Sponsors & Collaborators

  • Riverside Community Hospital, California

    lead OTHER

Principal Investigators

  • Afshin Rashtian, MD · Unaffilated

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-07-31
Primary Completion
2017-07-31
Completion
2018-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02070952 on ClinicalTrials.gov